Next Generation of Transgenic Plants: From Farming to Pharming

Alp Ayan, S. Meriç, Tamer Gümüş, Ç. Atak
{"title":"Next Generation of Transgenic Plants: From Farming to Pharming","authors":"Alp Ayan, S. Meriç, Tamer Gümüş, Ç. Atak","doi":"10.5772/intechopen.102004","DOIUrl":null,"url":null,"abstract":"The number of approaches related to recombinant protein production in plants is increasing rapidly day by day. Plant-based expression offers a safe, cost-effective, scalable, and potentially limitless way to rapidly produce recombinant proteins. Plant systems, which have significant advantages over animal and yeast recombinant protein production systems, are particularly promising for the large-scale production of antibodies and therapeutic proteins. Molecular pharming with transgenic plant systems become prominent among other production systems with its low cost, absence of human or animal pathogen contaminants, and the ability to use post-translational modifications such as glycosylation. The ability to produce recombinant pharmaceutical proteins in plant seeds, plant cells and various plant tissues such as hairy roots and leaves, through the stable transformation of the nuclear genome or transient expression, allows for the establishment of different production strategies. In particular, the rapid production of candidate proteins by transient expression, which eliminates the need for lengthy transformation and regeneration procedures, has made plants an attractive bioreactor for the production of pharmaceutical components. This chapter aimsto exhibit the current plant biotechnology applications and transgenic strategies used for the production of recombinant antibodies, antigens, therapeutic proteins and enzymes, which are used especially in the treatment of various diseases.","PeriodicalId":159021,"journal":{"name":"Genetically Modified Plants and Beyond [Working Title]","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetically Modified Plants and Beyond [Working Title]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.102004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

The number of approaches related to recombinant protein production in plants is increasing rapidly day by day. Plant-based expression offers a safe, cost-effective, scalable, and potentially limitless way to rapidly produce recombinant proteins. Plant systems, which have significant advantages over animal and yeast recombinant protein production systems, are particularly promising for the large-scale production of antibodies and therapeutic proteins. Molecular pharming with transgenic plant systems become prominent among other production systems with its low cost, absence of human or animal pathogen contaminants, and the ability to use post-translational modifications such as glycosylation. The ability to produce recombinant pharmaceutical proteins in plant seeds, plant cells and various plant tissues such as hairy roots and leaves, through the stable transformation of the nuclear genome or transient expression, allows for the establishment of different production strategies. In particular, the rapid production of candidate proteins by transient expression, which eliminates the need for lengthy transformation and regeneration procedures, has made plants an attractive bioreactor for the production of pharmaceutical components. This chapter aimsto exhibit the current plant biotechnology applications and transgenic strategies used for the production of recombinant antibodies, antigens, therapeutic proteins and enzymes, which are used especially in the treatment of various diseases.
下一代转基因植物:从种植到种植
与植物重组蛋白生产相关的方法日益增多。基于植物的表达提供了一种安全、经济、可扩展和潜在无限的方式来快速生产重组蛋白。与动物和酵母重组蛋白生产系统相比,植物系统具有显著的优势,尤其有希望大规模生产抗体和治疗性蛋白。在其他生产系统中,利用转基因植物系统进行分子制药具有成本低、不含人类或动物病原体污染物以及能够使用翻译后修饰(如糖基化)等优点。通过核基因组的稳定转化或瞬时表达,在植物种子、植物细胞和各种植物组织(如毛状根和叶片)中生产重组药物蛋白的能力,允许建立不同的生产策略。特别是,通过瞬时表达快速生产候选蛋白质,消除了冗长的转化和再生过程的需要,使植物成为生产药物成分的有吸引力的生物反应器。本章旨在展示当前植物生物技术在生产重组抗体、抗原、治疗性蛋白和酶方面的应用和转基因策略,这些技术尤其用于治疗各种疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信